Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices 1493 

gauge progress in meeting NBCCEDP 

program goals and monitor 

implementation activities, evaluate 

outcomes, and identify awardee 

technical assistance needs. In addition, 

findings will inform program 

improvement and help identify 

successful activities that need to be 

maintained, replicated, or expanded. 

CDC requests OMB approval for three 

years and for an estimated 1,162 annual 

burden hours. Participation is required 

for NBCCEDP awardees. There are no 

costs to respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hrs) 

NBCCEDP Recipients ..................................... Annual NBCCEDP Survey ............................. 71 1 46/60 

NBCCEDP Clinic-level Information Collection 

Instrument—Breast.

71 6 40/60 

NBCCEDP Clinic-level Information Collection 

Instrument—Cervical.

71 6 40/60 

Quarterly Program Update ............................. 71 4 32/60 

Service Delivery Projection Worksheet .......... 71 1 29/60 

MDEs .............................................................. 71 2 150/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2025–00161 Filed 1–7–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–25CH; Docket No. CDC–2024– 

0102] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Combating 

Antimicrobial Resistant Gonorrhea and 

Other STIs (CARGOS). CARGOS is a 

comprehensive strategy designed to 

streamline and improve the 

coordination of Antimicrobial 

Resistance (AR) surveillance and 

preparedness and response activities 

focused on Neisseria gonorrhoeae (GC) 

and expand capacity to include other 

STIs with emerging AR in the United 

States. 

DATES: CDC must receive written 

comments on or before March 10, 2025. 

ADDRESSES: You may submit comments 

identified by Docket No. CDC–2024– 

0102 by either of the following methods: 

b Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

b Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. Please note: 

Submit all comments through the 

Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7118; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of the existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of collecting 

information on those to respond, 

including using appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic responses; 

and 

5. Assess information collection costs. 

Proposed Project 

Combating Antimicrobial Resistant 

Gonorrhea and Other STIs (CARGOS)— 

New—National Center for HIV, Viral 

Hepatitis, STD, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The purpose of the proposed 

Combating Antimicrobial Resistant 


lotter on DSK11XQN23PROD with NOTICES1
1494 Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices 

Gonorrhea and Other STIs (CARGOS) 

data collection is to: (1) strengthen local 

epidemiologic capacity to detect, 

monitor, and respond to AR in STIs; (2) 

improve coordination of AR in STI 

preparedness and outbreak response 

activities; (3) enhance local laboratory 

testing for surveillance, reporting, and 

response; and (4) enhance coordination 

between epi-lab-health information 

technology for public health action. 

This information collection is important 

because: (1) effective treatment of 

gonorrhea is critical to gonorrhea 

control and prevention; (2) untreated or 

inadequately treated gonorrhea can 

cause serious reproductive health 

complications, such as infertility; (3) 

Neisseria gonorrhoeae (the bacterium 

that causes gonorrhea) has consistently 

demonstrated the ability to develop 

resistance to the antibiotics used for 

treatment and may be developing 

resistance to the last remaining 

treatment option recommended by CDC; 

and (4) antibiotic-resistant gonorrhea is 

extremely difficult to detect without 

enhanced surveillance and public 

health activities, such as CARGOS, 

because healthcare providers rarely 

perform or have access to resistance 

testing for individual patients. CARGOS 

will support rapid detection of resistant 

gonorrhea, get actionable information 

into the hands of healthcare providers 

(to support appropriate treatment of 

individual patients) and local health 

departments (to support rapid public 

health response to slow the spread of 

resistant infections in the community), 

and support multiple national public 

health strategies including the 2020– 

2025 National Action Plan for 

Combating Antibiotic-Resistant Bacteria 

(CARB) and STI National Strategic Plan 

for the United States 2021–2025. 

Jurisdictions participating in 

CARGOS applied as part of a 

competitive process and will participate 

voluntarily. As an overview of 

CARGOS, healthcare providers at 

participating clinics will collect 

specimens for N. gonorrhoeae culture 

testing from men and women seeking 

care for gonorrhea. Specimens that 

demonstrate N. gonorrhoeae (called 

‘‘isolates’’) will undergo antibiotic 

resistance testing at the local public 

health laboratory. Detection of 

resistance is rapidly communicated by 

the laboratory staff to the healthcare 

provider and health department to 

initiate a field investigation. The patient 

(from whom the resistant specimen was 

taken) will be interviewed to obtain 

demographics, clinical and risk factor 

information. For cases of gonorrhea of 

public health significance, recent sexual 

contacts of those cases will be 

interviewed by the health department 

and tested for gonorrhea. The 

participating health departments will 

collect and transmit to CDC 

demographic and clinical data about 

persons tested for and diagnosed with 

gonorrhea in the participating clinics, 

results of local antibiotic resistance 

testing, and information about field 

investigations. None of the data 

transmitted to CDC will contain any 

personally identifiable information. 

These data will be used by CDC to 

monitor and improve understanding of 

resistance and identify scalable, 

effective approaches to prevent the 

spread of resistance. Data will be 

transmitted through CDC’s Secure 

Access Management Services (SAMS). 

SAMS is an approved federal 

information technology system that 

provides authorized and validated users 

secure and encrypted access to CDC file 

transfer applications. The encrypted 

data will be stored in a secure CDC 

server with strictly controlled and 

restricted access rights. Isolates will be 

shipped each month to one of four 

Antibiotic Resistance Regional 

Laboratory Network (ARLN) laboratories 

for confirmatory antibiotic susceptibility 

testing and molecular characterization. 

Under the CARGOS protocol, local 

CARGOS data managers from each of 

the funded jurisdictions will abstract 

STD clinic data for patients tested for 

gonorrhea, receive resistance testing 

laboratory results from local public 

health laboratories, abstract data about 

field investigations, and will merge the 

data. Every month, the local CARGOS 

data manager will clean the data, 

remove personally identifiable 

information, and transmit the data to 

CDC. CDC estimates these data 

processes will take eight hours every 

month. Annually, the local CARGOS 

data manager will send a final 

cumulative data file for a total of 12 data 

transmissions/responses. 

Microbiologists at public health 

laboratories from each funded 

jurisdictions will conduct antibiotic 

resistance testing on all N. gonorrhoeae 

isolates on approximately 700 isolates 

each year (600 clinical isolates and 100 

control strains; each test is 

approximately 10 minutes). Every 

month, a laboratory data manager will 

abstract test results and securely send 

the datafile to the local CARGOS data 

manager. We estimate that laboratory 

data managers will spend approximately 

one hour each time they abstract, clean, 

and transmit project data. 

Health department staff will interview 

any person diagnosed with antibioticresistant gonorrhea or have a case of 

gonorrhea of public health significance 

(index case) and his/her sexual contacts. 

On average, two drug-resistant isolates 

are identified annually. These isolates 

will spur field investigations, which 

will result in two additional interviews 

each month. CDC estimates a total of 48 

interviews will occur annually at each 

site, for a total of 960 interviews each 

year across the funded sites. Each 

interview will take approximately 30 

minutes. 

CDC requests OMB approval for an 

estimated 3,875 annual burden hours. 

Respondents receive federal funds to 

participate in this project. There are no 

additional costs to respondents other 

than their time. 

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(hours) 

Total burden 

hours 

Public Health Laboratory Microbiologist.Attachment 3A .................................. 19 700 10/60 2,217 

Public Health Laboratory Data Manager.Attachment 3A .................................. 19 6 1 114 

Local CARGOS data manager/epidemiologist.Attachments 3A, 3B, 3C .................. 19 7 8 1,064 

Gonorrhea Patients and Sexual Contacts.Attachment 3C ................................. 960 1 0.5 480 

Total ........................................... ........................................................... ........................ ........................ ........................ 3,875 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 90, No. 5 / Wednesday, January 8, 2025 / Notices 1495 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2025–00164 Filed 1–7–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60–Day–25–0666; Docket No. CDC–2025– 

0001] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Pathogens of High Consequence, 

which assesses the incidence and 

prevalence of select high consequence 

pathogens of public health importance 

in acute care hospitals. In addition to 

the nine diseases approved for 

collection, the following three 

additional diseases are being added to 

the form: Influenza A (H5), Marburg, 

and Oropouche. 

DATES: CDC must receive written 

comments on or before March 10, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2025– 

0001 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road, NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

National Healthcare Safety Network 

(NHSN) (OMB Control No. 0920–0666, 

Exp. 12/31/2027)—Revision— 

Information Collection Request— 

National Center for Emerging and 

Zoonotic Infection Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The Division of Healthcare Quality 

Promotion (DHQP), National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC) collects 

data from healthcare facilities in the 

National Healthcare Safety Network 

(NHSN) under OMB Control Number 

0920–0666. NHSN provides facilities, 

health departments, states, regions, and 

the nation with data necessary to 

identify problem areas, measure the 

progress of prevention efforts, and 

ultimately eliminate healthcareassociated infections (HAIs) nationwide. 

NHSN also allows healthcare facilities 

to track blood safety errors and various 

HAI prevention practice methods such 

as healthcare personnel influenza 

vaccine status and corresponding 

infection control adherence rates. 

Enrollment in NHSN has 

continuously increased, with over 

37,000 actively reporting healthcare 

facilities across the U.S. Of the total 

enrolled healthcare facilities, there are 

over 6,000 acute care facilities. NHSN 

currently has eight components, and the 

collection of information is authorized 

by the Public Health Service Act (42 

U.S.C. 242b, 242k, and 242m (d)), 

(Attachment A1–A3). Data reported 

under NHSN’s Patient Safety 

Component are used to determine the 

magnitude of the healthcare-associated 

adverse events and trends in the rates of 

the events, in the distribution of 

pathogens, and in the adherence to 

prevention practices. Data will help 

detect changes in the epidemiology of 

adverse events resulting from new 

medical therapies and changing patient 

risks. Additionally, reported data is 

being used to describe the epidemiology 

of antimicrobial use and resistance and 

to better understand the relationship of 

antimicrobial therapy to this rising 

problem. 

NHSN’s data is used to aid in the 

tracking of HAIs and guide infection 

prevention activities/practices that 

protect patients. The Centers for 

Medicare and Medicaid Services (CMS) 

and other payers use these data to 

determine incentives for performance at 

healthcare facilities across the U.S. and 

surrounding territories, and members of 

the public may use some protected data 

to inform their selection among 

available providers.Each of these parties 

is dependent on the completeness and 

accuracy of the data. CDC and CMS 

work closely and are fully committed to 

ensuring complete and accurate 

reporting, which are critical for 

protecting patients and guiding 


lotter on DSK11XQN23PROD with NOTICES1